Current Research Studies

ANHL1931: A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemoimmunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

ANHL1931

  • Condition(s): Diffuse Large B-cell Lymphoma (DLBCL), Leukemia & Lymphoma, Newly diagnosed, Non-Hodgkin Lymphoma (NHL)
  • Phase: III
  • Clinicaltrials.gov ID: NCT04759586

What is the goal of the study?

The goal of this study to see if nivolumab + chemo-immunotherapy works better than chemo-immunotherapy alone. The study will be looking at the rate of remission, the rate of progression/relapse and the efficacy of these drugs.

Who can participate in the study?

This study may be a good for for children and young adults who are: 2 years or older Diagnosed with primary mediastinal B-cell lymphoma You can read more about the eligibility criteria for this study on clinicaltrials.gov. Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for your child.

Study Team: